Overview

A Twelve Week, Open Label Extension Study in Patients With Schizophrenia

Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
This is a 12-week, multi-center, open-label extension study designed to evaluate the longer-term safety, tolerability and effectiveness of lurasidone for the treatment of subjects with schizophrenia.
Phase:
Phase 3
Details
Lead Sponsor:
Sunovion
Treatments:
Lurasidone Hydrochloride